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Background: Analyses of the European Surveillance System on Contact Allergies (ESSCA)
database have focused primarily on the prevalence of contact allergies to the European base-
line series, both overall and in subgroups of patients. However, affected body sites have hith-
erto not been addressed.
Objective: To determine the prevalence of contact allergies for distinct body sites in patients
with allergic contact dermatitis (ACD).
Methods: Analysis of data collected by the ESSCA (www.essca-dc.org) in consecutively patch
tested patients, from 2009 to 2014, in eight European countries was performed. Cases were
selected on the basis of the presence of minimally one positive patch test reaction to the base-
line series, and a final diagnosis of ACD attributed to only one body site.
Results: Six thousand two hundred and fifty-five cases were analysed. The head and hand were
the most common single sites that ACD was attributed to. Differences between countries were
seen for several body sites. Nickel, fragrance mix I, cobalt and methylchloroisothiazolinone/-
methylisothiazolinone were the most frequent allergens reported for various body sites.
Conclusions: Distinct allergen patterns per body site were observed. However, contact aller-
gies were probably not always relevant for the dermatitis that patients presented with. The
possibility of linking positive patch test reactions to relevance, along with affected body sites,
should be a useful addition to patch test documentation systems.
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1 | INTRODUCTION
Previous analyses of the European Surveillance System on Contact
Allergies (ESSCA) database have focused primarily on the prevalence
of contact allergies. Many articles have reported on overall prevalence
or results in certain subgroups, such as occupational dermatitis
patients1 and children/adolescents,2 or for particular allergens.3,4
However, not much attention has been given to affected body sites,
apart from describing the overall prevalence of hand, leg and face der-
matitis according to the MOAHLFA index. Only facial dermatitis has
been highlighted once.5
Several articles beyond the ESSCA have, however, reported on
contact allergies linked to specific body sites, such as the hands, legs,
feet, and face.6–12 One publication reported on the frequency of derma-
titis at specific body sites, but not on specific contact allergies.13 Con-
tact allergies linked to various body sites in patients diagnosed with
allergic contact dermatitis (ACD) from the ESSCA database have not yet
been reported. This study aimed to identify and describe contact aller-
gies related to distinct body sites in patients diagnosed with ACD and
patch tested with the European baseline series in the ESSCA network.
2 | METHODS
2.1 | Study design and population
The analysis is based on data collected by the ESSCA network, as
described in previous publications.5,14 Clinical and demographic data,
along with patch test results, of all patients patch tested for suspected
ACD attributable to various potential exposures are documented
electronically in the departments participating in the ESSCA. These
use diverse data capture software, and partly the multilingual software
WINALLDAT/ESSCA provided by the ESSCA.15 Standardized patch testing
follows international recommendations.16 The study period was
January 2009 to December 2014.
Test results with the European baseline series (EBS) valid in the
study period, during which methylisothiazolinone (MI) 2000 ppm
aq. had been added, and the recommended test concentration of
methylchloroisothiazolinone (MCI)/MI had been increased from
100 to 200 ppm, and that of formaldehyde had been increased from
1% to 2%,17 were analysed.
As the objective of the study was to use a stringent definition of eligi-
ble patients (see below), the data analysed are restricted to those depart-
ments using the WINALLDAT/ESSCA or WINALLDAT/IVDK software, as this:
(a) uses a comparable catalogue of anatomical sites that can be unequivo-
cally mapped to the categories used in the present study; and (b) relies on
documentation whereby one or two final diagnoses are documented, and
up to three sites are documented for each diagnosis. In contrast, other
departments use other systems, which, while enabling the use of data, for
example, for describing the MOAHLFA index for each department, do not
allow selection based on the above-mentioned data structure. Thereby,
this study used data from eight European countries: Austria, Germany,
Italy, Lithuania, Poland, Spain, Switzerland, and The Netherlands.
2.2 | Inclusion and exclusion criteria
Inclusion criteria:
• Data documented in the ESSCA database between the years
2009 and 2014 by the use of WINALLDAT software (see above).
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• Patch tested with the EBS.
• Diagnosis of “allergic contact dermatitis”. Patients were permit-
ted to have additional diagnoses.
• Only one single anatomical site linked to the above ACD
diagnosis.
Exclusion criteria:
• More than one body site affected.
• No positive patch test reaction to the baseline series.
We have aggregated the body sites in the ESSCA into nine larger
groups: head, arm, hand, trunk, anogenital, leg, foot, generalized, and
other. See Supporting Information Table S1 for details of this aggre-
gating process. The group with generalized ACD represents patients
with widespread eczema. These patients will have more than three
major body sites affected.
2.3 | Statistical analysis
The pseudonymized data delivered by the participating departments
are pooled in the ESSCA data centre in Erlangen for further analysis,18
with R (version 3.4.2) software (www.r-project.org; last accessed
September 11, 2018). The maximum patch test reaction between day
3 and day 5 (inclusive) was aggregated as the patch test outcome.
Reactions designated as either +, ++ or +++ were classified as positive
(allergic); the remainder were designated as non-allergic. Descriptive
statistical analyses, partly stratified for country and site, followed per-
tinent guidelines.19,20 In particular, prevalence estimates concerning
baseline series allergens in the different subgroups were age-adjusted
and sex-adjusted to account for confounding.
3 | RESULTS
Figure 1 shows a study flow chart. Overall, 86 416 patients had been
tested with the baseline series in 2009 to 201421; 44 300 of these
were documented by the use of WINALLDAT software, and were thus
utilizable for the present analysis. We considered only the most recent
consultation if one patient had multiple consultations. Note:
• Of the 13 057 patients with a final diagnosis of ACD, 1997 had
no site information attributed to ACD; however, information on
the primary (initial) site of dermatitis was mostly available. This
was plugged in as appropriate site for the final diagnosis, but only
if just one final diagnosis of ACD was made, to avoid ambiguity of
the attribution. Therefore, 12 211 patients with information on at
least one site linked with a singular ACD diagnosis remained.
• Only one anatomical site (including plugged-in primary [initial]
site; see above) had been documented in 8285 patients, whereas
3230 had two sites documented, and 696 had three sites docu-
mented. Excluding patients with more than one site affected,
8285 patients remained in the analysis.
• After a comparison of patient characteristics, all further analyses
focused on the subgroup of patients with at least one positive
patch test reaction to an allergen of the baseline series
(n = 6255). The proportion of excluded patients did not vary
much between countries (P = 0.23, χ2 test).
Patients with positive patch test reactions to contact allergens
included in an additional series were not considered further, as the
tested additional series often have widely varying compositions. Fur-
thermore, among the 13 057 patients diagnosed with ACD, 4816 had
only one positive patch test reaction, and, in this latter subgroup,
Final diagnosis ACD
N = 13 057
Only one body site affected
N = 8285
Entering analyses
N = 6255
ESSCA
Tested with the baseline series
N = 86 416
Excluded/non-eligible (N = 42 113)
- Not tested in departments using the
WinAlldat/ESSCA or WinAlldat /IVDK software
Excluded/non-eligible (N = 4772)
- Multiple body sites reported: N = 3926
- Information on (primary)site missing: N = 846
Excluded/non-eligible (N = 2030)
- Nopositive reaction to the baseline series
Tested in selected departments 
N = 44 300
Excluded/non-eligible (N = 31 243)
- No final diagnosis of ACD
FIGURE 1 Study flow diagram. ACD, allergic contact dermatitis; ESSCA, European Surveillance System on Contact Allergies
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1360 (28.8%) had more than one site affected. These 1360 patients
were also excluded from further analysis.
A comparison of basic demographic and clinical characteristics
between the subgroup reacting positively to at least one baseline
series allergen and the subgroup without positive patch test reactions
to the baseline series is shown in Supporting Information Table S2
(MOAHLFA index). Males more often had negative baseline series
results (P < 0.0001, χ2 test).
Focusing on the 6255 patients with at least one positive patch
test reaction to contact allergens of the baseline series, the
MOAHLFA index for patients, stratified for country, is shown in
Table 1. The most striking differences were seen for sex (least males
in Lithuania, and most in Germany) and occupational dermatitis (least
cases in Spain, and most in Germany). The patch tested population—
as restricted in the present analysis—in Italy was strikingly younger
than the populations from the other countries.
The distribution of anatomical sites in patients with a diagnosis of
ACD attributed to one single body site is shown in Table 2, stratified
for country. Differences can be seen, mainly for the generalized sub-
group, ranging from 4.2% in Germany to >20% in The Netherlands
and Poland. The head and hand were clearly the most reported single
body sites that ACD was attributed to, and the anogenital area was
the least reported site (not taking the “other” category into account).
For the head and hand, large differences were seen between The
Netherlands and Germany, with the head being reported as the most
affected single site in The Netherlands (39.1%), and the hand being
most reported in Germany (45.7%). Conversely, Germany reported
the lowest percentage in the head category (22.7%), whereas The
Netherlands reported the lowest percentage in the hand category
(22.3%). ACD on the feet as the single body site was most reported in
Spain (7.7%).
The cases with a positive patch test reaction to the baseline series
(n = 6255) were subjected to analyses, stratified for body site, con-
cerning patch test results with the EBS. The results were adjusted for
sex and age (Table 3). Nickel, fragrance mix I, cobalt and MCI/MI were
the most frequently reported allergens for the various body sites.
Beyond these, differences between body parts became apparent,
including the following observations:
• Particularly frequent positive reactions to MCI/MI in patients with
ACD of the hands, for example, when compared with patients
with ACD of the feet.
• A high rating for colophonium and p-tert-butylphenol formalde-
hyde resin (PTBFR) in patients with ACD of the feet.
• Thiuram mix was a common contact allergen in patients with ACD
of the hands, whereas mercapto mix and 2-mercaptobenzothiazole
(MBT) were common in patients with ACD of the feet.
• Chromium was a common contact allergen in patients with ACD
of the extremities (arm/hand and leg/foot), and it was the most
frequent contact allergen in patients with ACD of the feet.
• p-Phenylenediamine (PPD) contact allergy was often found in patients
with ACD of the head, but also in patients with anogenital ACD.
• Myroxylon pereirae, colophonium, lanolin alcohol and paraben mix
were contact allergens that were often found in patients with
ACD of the legs.
• Positive patch test reactions to N-isopropyl-N0-phenyl-p-
phenylenediamine (IPPD) were prevalent in patients with ACD of
the head and upper extremities, but not in those with ACD of the
trunk and lower extremities.
• Positive patch test reactions to hydroxyisohexyl-3-cyclohexene
carboxaldehyde (HICC) were prevalent on all body sites, except in
patients with ACD of the feet. Also, fragrance mix II, which
includes HICC, was a relatively uncommon contact allergen
related to the feet.
• Positive patch test reactions to formaldehyde and the formalde-
hyde releaser quaternium 15 were prevalent in patients with ACD
of the hands, but mainly in patients with generalized ACD.
Crude prevalences of EBS contact allergens have been compiled in
Supporting Information Table S3. Also, tables have been compiled to
stratify for sex and age (dichotomized: <40 years and ≥ 40 years).
4 | DISCUSSION
In this study, we found that, in the ESSCA patch test database, the
head and hand were the most common distinct body sites that ACD
TABLE 1 MOAHLFA index for the 6255 patients who reacted positively to the baseline series with a diagnosis of allergic contact dermatitis
(ACD) attributed to a single body site, stratified for country
AT CH DE ES IT LT NL PL
Male 23.4 32.8 37.5 27.3 23.2 14.5 27.8 19.6
Occupational 24.5 21.1 41.2 15.9 23.6 19.7 18.6 35.9
Atopic eczema 24.5 17.8 26.4 9.1 11.2 7.4 34.7 9.3
Site of ACD: Hand 34.8 29.3 45.7 24.9 38.2 26.2 22.3 26.7
Site of ACD: Leg 9.2 8.7 10.0 7.3 2.7 9.5 2.9 5.5
Site of ACD: Face 20.3 26.0 16.4 12.1 12.6 27.1 20.9 13.3
Age ≥40 y 62.8 66.5 71.8 65.8 39.0 61.2 63.3 58.0
Total (n) 282 1002 981 1375 259 461 1293 602
Abbreviations: AT, Austria; CH, Switzerland; DE, Germany; ES, Spain; IT, Italy; LT, Lithuania; NL, The Netherlands; PL, Poland.
All figures are percentages. Note that the three sites (hand, leg, and face) do not relate to the primary site of contact dermatitis (irrespective of other infor-
mation such as diagnosis or patch test reactions) normally used for the MOAHLFA index, but to the same single sites used elsewhere in this analysis.
P-value of χ2 test for heterogeneity across countries: P < 0.0001 for all MOAHLFA items.
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was attributed to. Differences between countries were seen for multi-
ple body sites. Nickel, fragrance mix I, cobalt and MCI/MI were the
allergens that were most frequently reported for the various body
sites. Beyond these, differences between body parts were apparent.
Considering the MOAHLFA criteria, a difference in sex distribu-
tion between patients who reacted positively to the baseline series
and those who did not is obvious: there are more men with an ACD
diagnosis based on a positive patch test reaction to an allergen from
an additional series. It has been shown that woman are sensitized to
allergens from the EBS more often, possibly because they tend to use
products such as cosmetics more than men, and many constituents of
these products are allergens included in the EBS.22,23
The hands and the head were the most common single sites to
which a diagnosis of ACD was attributed in our study sample. These
sites were also found to be common sites of dermatitis at presenta-
tion in other studies.24,25 This once again justifies the choice of adding
facial dermatitis to the MOAHLFA criteria.26 Also, the feet and legs
are common sites in both adults13 and children.27–29
4.1 | Anatomical site “head”
ACD of the head was most often reported in The Netherlands and
Lithuania, and least often in Germany and Spain. Note that, in our
study, “head” includes, but is not limited to, “face” as the anatomical
site. One large study was performed on facial dermatitis and patch
testing by Schnuch et al in 18 572 patients.9 They compared positive
patch test reactions in men and woman. Positive patch test reactions
to nickel, fragrance mix, PPD, lanolin alcohol and HICC were signifi-
cantly more common in women. Only epoxy resin gave significantly
more positive patch test reactions in men. Other research on facial
ACD and patch tests was performed in several smaller studies.30–37 In
these studies, a high prevalence of contact allergy to mainly nickel,
fragrances, PPD and MCI/MI was found, which corresponds to our
results. In the study by Kasemsarn et al, the clinical relevance of posi-
tive patch test reactions was determined for each case. Positive patch
test reactions to metals and hairdressing product-related allergens
were found to be most often of clinical relevance. Also, positive patch
test reactions to colophonium were frequently clinically relevant.33 In
our study, positive patch test reactions to colophonium were not
more commonly found in patients with ACD of the head than in those
with ACD of other body parts. However, we cannot comment on the
clinical relevance of the positive patch test reactions, which has hith-
erto not been collected in a standardized and systematic way in the
ESSCA network. For the thiuram mix, we found a prevalence of 3.5%
in patients with ACD of the head, which is similar to the percentage
found by Schwensen et al in Denmark.38
4.2 | Anatomical site “hand”
ACD of the hands was most often diagnosed in Germany and Italy,
and least often in The Netherlands. Especially for Germany, this might
be explained by a higher prevalence of (and focus on) occupational
cases, which are often associated with ACD of the hands.39 Although
many occupational cases were also seen in Poland, here the hands
were much less often affected than in Germany. It must be noted that
occupational cases can be allergic as well as irritant in nature. More
occupational cases in Poland may therefore have an irritant aetiology.
In studies performed with >200 subjects with hand eczema tested
consecutively with baseline allergens, contact allergies to nickel, pre-
servatives, fragrances and cobalt were most often reported, corre-
sponding to our results.40–46 In addition, in consecutively tested
hospital patients with hand eczema in Portugal and China, contact
allergies to chromium and PPD were also often found to be highly
prevalent.47,48 Interestingly, in a cross-sectional analysis of data from
the North American Contact Dermatitis Group between 1994 and
2004, Warshaw et al found that the most common allergens in hand
eczema patients were the preservatives quaternium 15 and formalde-
hyde, before nickel and fragrance mix. In that study, clinical relevance
was determined, and these preservatives also proved to be most often
relevant.7
4.3 | Specific allergens
Contact allergies to nickel, fragrance mix I, cobalt and MCI/MI are
common and, as found in our study, not specifically related to certain
body sites. This is reflected by the fact that these allergens were the
most frequently reported allergens for the various body sites. In other
words, one can frequently expect a positive patch test reaction to one
of these allergens, regardless of the site of dermatitis.
TABLE 2 Distribution of anatomical sites of allergic contact dermatitis of a single body site in 6255 patients who reacted positively to the
baseline series, stratified for country
Country Tested Head Arm Hand Trunk Anogenital Leg Foot Generalized
AT 282 96 (34.0) 17 (6.0) 98 (34.8) 19 (6.7) 7 (2.5) 26 (9.2) 5 (1.8) 12 (4.3)
CH 1002 339 (33.8) 50 (5.0) 294 (29.3) 58 (5.8) 52 (5.2) 87 (8.7) 38 (3.8) 73 (7.3)
DE 981 223 (22.7) 34 (3.5) 448 (45.7) 57 (5.8) 20 (2.0) 98 (10.0) 45 (4.6) 41 (4.2)
ES 1375 325 (23.6) 125 (9.1) 342 (24.9) 239 (17.4) 35 (2.5) 100 (7.3) 106 (7.7) 91 (6.6)
IT 259 78 (30.1) 13 (5.0) 99 (38.2) 28 (10.8) 1 (0.4) 7 (2.7) 15 (5.8) 17 (6.6)
LT 461 163 (35.4) 10 (2.2) 121 (26.2) 23 (5.0) 34 (7.4) 44 (9.5) 8 (1.7) 48 (10.4)
NL 1293 505 (39.1) 23 (1.8) 288 (22.3) 41 (3.2) 29 (2.2) 37 (2.9) 63 (4.9) 306 (23.7)
PL 602 177 (29.4) 20 (3.3) 161 (26.7) 39 (6.5) 12 (2.0) 33 (5.5) 31 (5.1) 128 (21.3)
Total 6255 1906 (30.5) 292 (4.7) 1851 (29.6) 504 (8.1) 190 (3.0) 432 (6.9) 311 (5.0) 716 (11.4)
AT, Austria; CH, Switzerland; DE, Germany; ES, Spain; IT, Italy; LT, Lithuania; NL, The Netherlands; PL, Poland.
Figures are shown as overall number (percentage within country). n = 53 (0.8%) patients with “other” single sites not shown.
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The finding that MCI/MI allergy was most often found in patients
with ACD of the hands is in line with results from a large study using
data from North America, in which individuals with MCI/MI and MI
allergy were significantly more likely to have hand dermatitis than the
general patch tested population.49 In a worldwide multicentre study,
the face was also reported as a frequent location.50 The higher preva-
lence of MCI/MI allergy for these body sites could very well be
explained by the fact that the hands and face are preferred locations
for leave-on products, which lead to contact allergy more readily than
rinse-off products51; moreover, both sites are also exposed to rinse-
off products. The high prevalence that we found highlights once more
how common contact allergy to this preservative has become during
the current epidemic, and emphasizes the importance of the ban on
MI in leave-on products.52
Concerning rubber allergens, we found distinct patterns for
thiuram mix and mercapto mix: thiuram mix was more often positive
in patients with ACD of the hands, whereas contact allergy to mer-
capto mix was more often diagnosed in patients with ACD of the feet.
This is in line with many previous studies,7,10,53–58 and might be
explained by higher release of thiuram mix from rubber gloves
(as compared with MBT).59 Ingredients from the mercapto mix might
indeed be more common in shoes and boots (although closely fol-
lowed by thiuram mix).60,61 Colophonium and PTBFR are also com-
mon ingredients in shoes, which frequently cause ACD, and this is
confirmed again in our data.60 However, especially concerning
gloves, the allergies that we found could be attributable to sensitiza-
tion in the past. Bergendorff et al showed that there were no thiur-
ams present in protective gloves used in healthcare in southern
TABLE 3 Sex-adjusted and age-adjusted prevalences with 95% confidence intervals of positive reactions to the baseline series haptens stratified for
body site
Allergen
Head,
n = 1906
Arm,
n = 292
Hand,
n = 1851
Trunk,
n = 504
Anogenital,
n = 190
Leg,
n = 432
Foot,
n = 311
Generalized,
n = 716
Nickel 38.0 (35.6-40.3) 48.4 (42.9-53.9) 34.4 (32.3-36.4) 53.8 (49.5-58.2) 30.9 (24.3-37.5) 30.5 (24.2-36.9) 31.7 (26.4-37.0) 43 (39.2-46.8)
Cobalt 10.7 (9.1-12.4) 14.6 (10.2-19.0) 16.0 (14.3-17.7) 14.8 (11.5-18.2) 10.1 (5.4-14.8) 13.1 (8.0-18.2) 24.5 (19.4-29.6) 18.2 (15.0-21.3)
Chromium 5.0 (3.8-6.2) 10.3 (6.6-14.1) 10.2 (8.8-11.6) 7.2 (4.8-9.6) 3.3 (0.2-6.5) 15.1 (9.6-20.6) 42.8 (37.0-48.6) 13.5 (10.8-16.2)
Fragrance mix I 22.2 (19.6-24.7) 16.5 (12.3-20.6) 16.2 (14.5-17.9) 16.9 (13.6-20.3) 25.9 (19.0-32.8) 25.8 (20.2-31.4) 9.4 (6.2-12.7) 19.5 (16.5-22.5)
Fragrance mix II 10.5 (8.8-12.2) 10.3 (6.7-13.8) 10.1 (8.7-11.4) 11.8 (8.9-14.7) 17.9 (11.6-24.3) 11.9 (7.9-15.9) 4.1 (1.9-6.3) 13.5 (10.9-16.1)
HICC 5.5 (4.2-6.8) 3.6 (1.4-5.9) 4.8 (3.8-5.7) 4.7 (2.8-6.6) 5.6 (1.1-10.2) 3.4 (0.6-6.2) 1.0 (0.0-2.0) 4.5 (2.9-6.0)
Myroxylon
pereirae
(balsam
of Peru)
15.0 (12.8-17.2) 9.0 (5.8-12.2) 11.5 (10.1-13.0) 12.2 (9.4-15.1) 21.7 (15.1-28.4) 27.6 (22.1-33.1) 11.8 (8.2-15.4) 14.2 (11.7-16.7)
Colophonium 6.7 (5.2-8.2) 4.2 (1.8-6.6) 8.3 (7.0-9.5) 6.2 (3.9-8.4) 6.1 (2.1-10.0) 14.1 (9.1-19.0) 12.9 (9.0-16.9) 7.3 (5.4-9.3)
Formaldehyde 3.2 (2.1-4.4) 2.9 (0.8-4.9) 5.6 (4.6-6.7) 4.4 (2.5-6.4) 3.0 (0.8-5.2) 1.2 (0.4-2.0) 3.2 (1.1-5.2) 6.2 (4.3-8.0)
Paraben mix 1.7 (0.9-2.4) 1.3 (0.0-2.7) 1.5 (0.9-2.1) 1.8 (0.6-3.0) 5.6 (1.3-9.9) 4.9 (2.3-7.4) 0.9 (0.0-2.0) 2.5 (1.4-3.6)
Quaternium 15 1.1 (0.4-1.8) 0.0 (0.0-1.0) 1.4 (0.9-2.0) 0.4 (0.0-1.0) 0.4 (0.0-1.1) 1.2 (0.0-2.8) 0.5 (0.0-1.5) 2.2 (1.1-3.4)
MCI/MI 15.4 (13.3-17.4) 9.4 (5.9-12.8) 22.4 (20.5-24.4) 13.8 (10.7-17.0) 15.6 (10.2-20.9) 9.3 (5.5-13.1) 6.1 (3.2-9.0) 18.2 (15.2-21.2)
MI 8.0 (6.5-9.4) 5.3 (2.6-8.0) 9.8 (8.5-11.2) 8.0 (5.5-10.5) 3.8 (0.4-7.2) 5.5 (2.2-8.8) 4.8 (2.2-7.3) 9.9 (7.6-12.2)
MDBGN 6.8 (5.2-8.4) 3.5 (1.4-5.6) 7.1 (5.9-8.3) 6.5 (4.4-8.6) 6.9 (3.5-10.4) 9.1 (5.5-12.6) 3.6 (1.4-5.8) 10.0 (7.8-12.2)
PPD 9.6 (8.0-11.2) 5.2 (2.4-8.0) 5.5 (4.5-6.6) 4.7 (2.9-6.5) 8.6 (4.1-13.1) 3.5 (1.6-5.4) 3.4 (1.5-5.3) 5.7 (3.9-7.4)
Benzocaine 1.0 (0.3-1.6) 1.2 (0.0-2.5) 0.4 (0.1-0.7) 1.1 (0.3-1.9) 4.1 (1.4-6.8) 1.2 (0.4-2.0) 0.5 (0.0-1.1) 0.4 (0.0-0.8)
Clioquinol 0.8 (0.1-1.6) 0.0 (0.0-1.0) 0.2 (0.0-0.4) 0.4 (0.0-1.0) 1.7 (0.0-3.5) 0.5 (0.0-1.1) 0.3 (0.0-0.8) 0.6 (0.1-1.1)
Budesonide 1.2 (0.3-2.0) 1.9 (0.2-3.6) 0.8 (0.4-1.2) 1.7 (0.6-2.9) 1.6 (0.0-3.4) 0.9 (0.2-1.6) 1.3 (0.0-2.5) 1.3 (0.4-2.3)
Tixocortol
pivalate
0.9 (0.4-1.3) 1.0 (0.0-2.4) 0.7 (0.3-1.1) 1.6 (0.6-2.7) 1.0 (0.0-2.4) 1.6 (0.0-3.3) 1.0 (0.0-2.1) 2.1 (1.0-3.2)
Neomycin
sulfate
1.4 (0.7-2.1) 1.5 (0.0-2.9) 1.0 (0.5-1.4) 2.1 (0.8-3.4) 2.0 (0.0-4.0) 2.1 (1.1-3.2) 0.4 (0.0-1.2) 2.5 (1.3-3.7)
Thiuram mix 3.3 (2.1-4.5) 5.1 (2.5-7.7) 12.6 (11.1-14.2) 2.5 (1.1-4.0) 2.1 (0.0-4.9) 3.0 (1.8-4.2) 5.1 (2.5-7.7) 3.3 (1.9-4.7)
MBT 0.8 (0.2-1.4) 0.3 (0.0-0.8) 3.1 (2.3-3.9) 0.7 (0.0-1.6) 0.4 (0.0-1.1) 0.9 (0.2-1.6) 7.9 (4.6-11.2) 1.6 (0.7-2.6)
Mercapto mix 0.5 (0.2-0.8) 0.5 (0.0-1.2) 2.8 (2.1-3.6) 1.1 (0.1-2.1) 0.5 (0.0-1.4) 1.2 (0.4-2.0) 8.1 (4.8-11.4) 1.2 (0.5-2.0)
IPPD 2.1 (1.3-2.8) 2.6 (0.5-4.7) 2.3 (1.6-2.9) 0.3 (0.0-0.7) 0.4 (0.0-1.1) 0.5 (0.0-1.1) 0.5 (0.0-1.2) 2.1 (0.9-3.3)
Lanolin alcohol 5.6 (4.1-7.2) 3.4 (1.3-5.5) 4.1 (3.2-5.0) 3.1 (1.6-4.7) 5.2 (2.1-8.2) 10.1 (6.5-13.7) 5.7 (3.0-8.4) 6.8 (4.8-8.8)
SL mix 1.0 (0.2-1.9) 0.5 (0.0-1.6) 1.3 (0.8-1.9) 0.8 (0.1-1.4) 0.8 (0.0-1.8) 0.7 (0.1-1.3) 1.1 (0.0-2.3) 1.3 (0.4-2.2)
Primin 0.3 (0.1-0.5) 0.0 (0.0-1.0) 0.2 (0.0-0.4) 0.0 (0.0-0.6) 0.8 (0.0-1.8) 0.0 (0.0-0.7) 0.0 (0.0-1.0) 0.9 (0.1-1.7)
Epoxy resin 4.2 (2.7-5.7) 3.5 (1.2-5.7) 4.0 (3.1-5.0) 2.1 (0.7-3.5) 2.8 (0.5-5.1) 3.6 (0.7-6.4) 2.1 (0.4-3.8) 3.7 (2.2-5.1)
PTBFR 1.3 (0.8-1.8) 2.2 (0.4-3.9) 1.5 (0.9-2.0) 1.9 (0.6-3.2) 0.8 (0.0-2.0) 2.8 (0.5-5.2) 8.5 (5.3-11.7) 2.6 (1.4-3.8)
HICC, hydroxyisohexyl 3-cyclohexene carboxaldehyde; IPPD, N-isopropyl-N0-phenyl-p-phenylenediamine; MBT, 2-mercaptobenzathiazole; MCI, methyl-
chloroisothiazolinone; MDBGN, methyldibromo glutaronitrile (dibromodicyanobutane); MI, methylisothiazolinone; PPD, p-phenylenediamine; PTBFR,
p-tert-butylphenol formaldehyde resin; SL, sesquiterpene lactone.
n = 6255 patients were tested with all 29 allergens included in this analysis, and reacted positively to at least one of these. n = 53 patients with “other” sin-
gle sites not shown.
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Sweden.62 Uter et al described a downward trend of thiuram allergy
for healthcare workers, suggesting that most manufacturers may
have replaced thiurams with dithiocarbamates.63 However, patch
testing with thiurams is regarded as suitable for diagnosing contact
allergy to dithiocarbamates, because these substances constitute a
redox pair.64
Chromium was a common contact allergen in patients with ACD
of the extremities, and especially so in patients with ACD of the feet.
Considering the wide range of sources of chromium exposure, the fre-
quency found for the extremities (including the hands and feet) is not
surprising.65 The most logical explanation for chromium allergy being
related to ACD of the feet is that footwear containing leather is the
main source of sensitization. In previous studies, it was found that
chromium was the most common allergen in patients with foot
dermatitis,66,67 and that it was significantly associated with leg and
foot dermatitis in women.68 Our finding emphasizes the importance
of EU directive No. 301/2014 stating that, from May 2015, leather
articles placed on the markets of European countries that come into
contact with the skin should not contain >3 ppm chromium(VI).69 We
therefore expect a decrease in chromium contact allergy in future
years.
PPD is a known common contact allergen for ACD of the head.70
We also found a quite high prevalence of PPD contact allergy in
patients with anogenital ACD. This might partly be explained by
cross-reactions with benzocaine,71 which is used in topical formula-
tions that are applied anally and that we also found to be prevalent
for this body site.
Allergy to the antioxidant/antiozonant IPPD was strikingly more
often found in patients with ACD of the head and upper extremities
(arm and hand) than in those with ACD of the trunk and lower extrem-
ities. Although sometimes causing ACD on the feet because of its
presence in heavy boots,72 IPPD is more often reported to cause ACD
on the upper body parts that come into direct contact with industrial
rubbers for heavy-duty applications, such as tires.73,74 Furthermore, it
has been shown that cross-reactions between PPD and IPPD can
occur.71
A profile of contact allergens associated with the use of topical
drugs was found for patients with ACD of the legs (M. pereirae,
colophonium, lanolin alcohol, and paraben mix). This has also been
found in previous studies, and mainly in elderly patients, probably
because of the use of topical agents for the treatment of stasis
dermatitis and ulceration of the lower legs.75 However, over the
years, a decrease has been seen in the frequency of contact aller-
gies in these patients, possibly implying that the treatment of sta-
sis dermatitis and leg ulceration has improved in terms of using
less topical and less allergenic preparations.12 This might be
explained by an increase in the use of wound dressings instead of
topical formulations to treat these patients. Conversely, positive
patch test reactions to wound dressings are now becoming more
common.11
The fact that allergy to HICC, together with allergies to other fra-
grances, was least often seen in patients with ACD of the feet is in
accordance with previous studies.10,76 Apparently, patients with foot
dermatitis constitute a quite distinctive entity. The most logical expla-
nation could be that patients with foot dermatitis have had less
exposure to cosmetic products. We expect the prevalence of HICC
contact allergy to decrease in future years, as EU directive
No. 2017/1410 bans HICC, stating that, from August 2021, cosmetic
products containing HICC shall not be made available on the EU
market.77
Formaldehyde is often found in cosmetics. In a recent Danish
study, it was mostly found in creams, shampoos, and soaps.78 The fact
that these products are often used over the whole body most likely
explains the prevalence of formaldehyde and quaternium 15 contact
allergy in patients with generalized ACD, and also in patients with
ACD of the hands.
A limitation of our study is that it is not certain that the diagno-
sis of ACD was always based on a clinically relevant positive patch
test reaction to an allergen in the EBS. Additional series are often
tested, and the diagnosis could very well been based on a positive
patch test reaction to an allergen from an additional series, while a
positive patch test reaction to an EBS allergen was also present, but
not currently relevant. Another limitation is that the relevance of
individual positive patch test reactions was not taken into account,
as it was not registered systematically in all centres. To overcome
this problem in the future, an “extended ESSCA” database has been
developed as a concept, providing the possibility of very precisely
linking positive patch test reactions to body sites, along with current
and past relevance for the dermatitis that the patient presented
with.79 Furthermore, a small subgroup was not included in the ana-
lyses. This concerns the cases that had only one positive patch test
reaction to the EBS but had multiple sites involved. Exclusion of
cases with multiple body sites affected removed the possibility of
investigating frequent concomitant sites of ACD. Conversely, inclu-
sion would have made it impossible to keep a clear-cut group with
isolated affected body sites. We have deliberately included patients
with generalized ACD for comparison, although it can be argued that
generalization does not represent an actual single site. We chose to
include this group because it represents patients with widespread
eczema, for whom it is also important to define the most frequently
found contact allergies. Furthermore, the subgroup of patients in
our study with generalized ACD (with “generalized” entered as one
single site) represented a substantial percentage of our study
population.
In conclusion, in the analysed ESSCA data, we found that most
cases of ACD concerning a single isolated body site are attributed to
the head and hands. Multiple allergen patterns per body site can be
observed. Contact allergies to, especially, nickel, fragrance mix I,
cobalt and/or MCI/MI were common for the period between 2009
and 2014. However, contact allergy to these allergens was not found
to be specifically related to a certain body site. Adding the possibility
of linking positive patch test reactions to relevance, along with the
affected body sites, should be an important addition to data capture
systems, such as WINALLDAT/ESSCA.
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